Medpace (MEDP)

Executive Summary

Medpace Holdings is a leading global contract research organization (CRO) that provides comprehensive clinical development services, including clinical pharmacology, laboratory services, bioanalytical testing, ECG monitoring, and imaging core labs. With over 30 years of organic growth and a fully integrated service model, Medpace serves biotechnology and pharmaceutical companies across all therapeutic areas and clinical trial phases. The company has a strong track record of operational excellence and customer retention, underpinned by its specialized facilities and depth of expertise. As a public company with a valuation of approximately $12.9 billion, Medpace continues to benefit from the increasing outsourcing of drug development by biopharma firms. Its current pipeline includes active trials such as TNX-103 in pulmonary hypertension (Phase 3) and Azeliragon in glioblastoma (Phase 2), positioning the company for potential near-term revenue growth. With a disciplined approach to cost management and a robust backlog of orders, Medpace remains well-positioned to capitalize on the growing demand for clinical trial services.

Upcoming Catalysts (preview)

• Q3 2026Azeliragon Phase 2 data readout in glioblastoma40% success
• Q4 2026TNX-103 Phase 3 interim analysis in pulmonary hypertension60% success
• Q2 2026Q2 2026 earnings release and backlog update90% success